Anlotinib is a novel multitarget tyrosine kinase inhibitor, which has been indicated to inhibit both tumor angiogenesis and signal transduction pathways associated with proliferation. The main proposed mechanism of anlotinib inhibiting tumor angiogenesis is that anlotinib inhibits the activation of VEGFR2, PDGFRβ and FGFR1, and downstream ERK signal transduction. The aim of the present study was to systematically evaluate the efficacy and safety of third-line treatment with anlotinib for advanced non-small cell lung cancer (NSCLC). To meet this aim, studies published up to February 2022 were searched in PubMed, Web of Science, the Cochrane Library and several Chinese databases. Only randomized controlled trials (RCTs) were included and a metaanalysis was performed using RevMan 5.3 software. A total of 18 RCTs were identified and included in the present study, comprising 1,658 patients. The anlotinib treatment group was indicated to be better than the control group at prolonging progression-free survival [hazard ratio (HR), 0.33; 95% confidence interval (95% CI), 0.28-0.37] and overall survival (HR, 0.70; 95% CI, 0.60-0.81). Anlotinib also provided a significant improvement in the disease control rate [risk ratio (RR), 1.51; 95% CI, 1.27-1.79], objective response rate (1.75, 95% CI, 1.51-2.03) and Karnofsky performance status (mean difference, 9.85; 95% CI, 6.26-13.43). Compared with the control group, the incidence of adverse events (AEs), such as hypertension and hemoptysis, was increased by anlotinib. Through subgroup analysis, it was determined that, compared with the placebo, the incidence of AEs was increased by anlotinib, although compared with other therapeutic drugs, no significant differences were observed. In conclusion, the findings of the present study suggested that the thirdline treatment of advanced NSCLC with anlotinib is more effective compared with other control measures and that the AEs are also controllable. However, given the limitations of the quantity and the quality of the included studies, further studies are required to gain a more complete understanding of the effects of anlotinib.

To research the immunological characteristics of antigen complementarity determining the region of T cell receptor α chain in peripheral blood of patients with Takayasu's arteritis, and to provide the new theoretical basis for the diagnosis and treatment of Takayasu's arteritis. Five untreated patients with Takayasu arteritis in Capital medical university affiliated Anzhen Hospital, China, were collected from June 2019 to December 2019. Four healthy peripheral blood samples were matched as the control group. Separate peripheral blood mononuclear cells and extract RNA for reverse transcription. Specific primers obtained nucleotides in the CDR3 region of the TCR α chain, high-throughput sequencing was performed, and the quality of samples was evaluated by principal component analysis. R software was used for statistical analysis and drawing, and a nonparametric test was used to analyze the differences between the two groups. The results of the principal component analysis showed that the TAK group was in the sample set. D50 analysis showed that the diversity of TCR in the TAK group was significantly higher than in the control group. The expression of 3 genes in the V region was significantly higher in patients than in the control group. 196 VJ rearrangement genes are significantly different between the two groups, of which 47 rearrangement genes in the control group are lower than those in the TAK group, and 149 rearrangement genes in the control group are higher than those in the TAK group. Patients with Takayasu's arteritis have a unique CDR3 library, and there are obvious disease-related T cell clones. These characteristic genes may be a marker for early diagnosis and provide a new theoretical basis for treating Takayasu arteritis.

AimProvide an overview and a systematic evaluation of the evidence quality on the association between non-coding RNAs (ncRNAs) and prognosis value for gastrointestinal cancers (GICs).MethodsWe searched the literature from three electronic databases: Pubmed, Embase, and Web of science, then carefully screened and extracted the primary information and results from the included articles. We use A measurable systematic review and meta-analysis evaluation tool (AMSTAR2) to evaluate the quality of methodology and then use the Grading of Recommendations Assessment 2, Development and Evaluation guideline (GRADE) make sure the reliability of the meta-analysis.ResultsOverall, 182 meta-analyses from 58 studies were included in this study. Most of these studies are of low or very low quality. Using the scoring tool, we found that only two meta-analyses were rated as high reliability, and 17 meta-analyses were rated as medium reliability.ConclusionsAlthough ncRNA has good prognostic value in some studies, only a tiny amount of evidence is highly credible at present. More research is needed in the future.PROSPERO registration numberCRD42022382296.